Biosimilars in rheumatology: What the clinician should know

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Castañeda Hernández, Gilberto ^a,b   González Ramírez, Rodrigo ^a   Kay, Jonathan ^c   Scheinberg, Morton A ^d,e  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

^b Centro Latinoamericano de Pesquisa em Biologicos   (Brazil)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d AACD   (Brazil)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193213     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000010     Document Type: Review

References (32)

1. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology-"O brave new world". Nat Rev Rheumatol 2012;8:430-6.
2. Castañeda-Hernández G, Szekanecz Z, Mysler E, et al. Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine 2014;81:471-7.
3. Celltrion. About us. What's new. http://www.celltrion.com/en/company/notice-view.asp?idx=456&code=ennews&intNowPage=1&menu-num=&align-year=all (accessed 18 Apr 2015).
4. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014;42:177-83.
5. GaBi Online-Generics and Biosimilars Initiative. Infliximab "similar biologic" receives Indian approval. http://www.gabionline.net/layout/ set/print/Biosimilars/News/Infliximab-similar-biologic-receives-Indianapproval (accessed 18 Apr 2015).
6. GaBi Online-Generics and Biosimilars Initiative. Adalimumab similar biologic launched in India. http://gabionline.net/Biosimilars/ News/Adalimumab-similar-biologic-launched-in-India (accessed 18 Apr 2015).
7. Robinson R. HD203 biosimilar is clinically equivalent to etanercept. http://www.hcplive.com/conferences/acr-2014/HD203-Biosimilar-is- Clinically-Equivalent-to-Etanercept (accessed 18 Apr 2015).
8. Dörner T, Strand V, Castañeda-Hernández G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013;72:322-8.
9. Yi S, Kin SE, Park MK, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, cross-over study in healthy volunteers. BioDrugs 2012;26:177-84.
10. Kaur P, Chow V, Zhang N, et al. A randomized, single-blind, singledose, three-arm, parallel group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab: results of comparison with adalimumab (EU). Ann Rheum Dis 2014;73(Suppl 2):479 [Abstract].
11. Araújo F, Cordeiro I, Teixeira F, et al. Pharmacology of biosimilar candidate drugs in Rheumatology: a literature review. Acta Rheumatol Port 2014;39:19-26.
12. Scheinberg MA, Azevedo VF. Biosimilars in rheumatology: perspectives and concerns. Rheumatology (Oxford) 2014;53:389-90.
13. Kay J, Smolen JS. Biosimilars to treat inflammatory arthritis: the challenge of proving identity. Ann Rheum Dis 2013;72:1589-93.
14. Cortés J, Curigliano G, Diéras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. Breast Cancer Res Treat 2014;144:233-9.
15. Pidgen AW. Statistical aspects of bioequivalence-a review. Xenobiotica 1992;22:881-93.
16. Patel BV. Bioequivalence: an overview of statistical concepts. Indian J Pharmacol 2004;36:209-16.
17. Njue C. Statistical considerations for confirmatory clinical trials for similar biotherapeutic products. Biologicals 2011;39:266-9.
18. Yoo DH, Hrycaj P, Miranda P, et al. A randomized, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-20.
19. Fletcher M. Biosimilars clinical development program: confirmatory clinical trials: a virtual/simulated case study comparing equivalence and non-inferiority approaches. Biologicals 2011;39:270-7.
20. World Health Organization Expert Committee on Biological Standardization. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). Geneva, 19-23 October 2009. [http://www.who.int/ biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf (accessed 18 Apr 2015).
21. Canadian Agency for Drugs and Technologies in Health. Subsequent Entry Biologics-Emerging Trends in Regulatory and Health Technology Assessment Frameworks. https://www.cadth.ca/ subsequent-entry-biologics-emerging-trends-regulatory-and-healthtechnology- assessment-frameworks (accessed 18 Apr 2015).
22. Bae SC, Kim JS, Choe JY, et al. A randomized, double-blind, phase 3, equivalence trial comparing the etanercept biosimilar, HD203, with etanercept (Enbrel®), in combination with methotrexate (MTX) in patients with rheumatoid arthritis (RA) [Abstract]. Arthitis Rheumatol 2014;66:2825.
23. Kay J, Chopra A, Chandrashekara S, et al. A phase 3, randomized, double-blind, active comparator study of the efficacy and safety of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis on stable methotrexate doses. Ann Rheum Dis 2014;73 (Suppl 2):64. [Abstract].
24. Kay J, Wyand M, Chandrashekara S, et al. BOW015, a biosimilar infliximab, in patients with active rheumatoid arthiritis on stable methotrexate doses: 54-week results of a randomized, double-blind, active comparator study [Abstract]. Arthitis Rheumatol 2014;66:3538.
25. Scheinberg M, Castañeda-Hernández G. Antitumor necrosis factor patent expiration and the risks of biocopies in clinical practice. Arthritis Res Ther 2014;16:501.
26. Kay J. Biosimilars: a regulatory perspective from America. Arthritis Res Ther 2011;13:112.
27. Rondón F, Bautista A, Salazar JC, et al. Etanar therapy in real-life patients with rheumatoid arthritis. Arthritis Rheum 2010;62 (Suppl 10):1811.
28. Moctezuma JF, Martínez A, Enkerlin H, et al. Comparative, randomized, simple blind to evaluate efficacy and safety of Infinitam® (etanercept), associated with methotrexate compared with Enbrel® (etanercept) associated with methotrexate in patients with moderate and severe rheumatoid arthritis. Ann Rheum Dis 2013;72 (Suppl 3):A234. [Abstract].
29. Comisión Federal para la Protección contra Riesgos Sanitarios. Comunicado a los Profesionales de la Salud. Reacciones anafilácticas por el uso de Rituximab. 4 de abril de 2012. http://www. cofepris.gob.mx/AZ/Paginas/Farmacovigilancia/Comunicados.aspx (accessed 18 Apr 2015).
30. Arredondo-Garza T, Majluf-Cruz A, Vela-Ojeda J, Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma. Arch Med Res 2013;44:549-54.
31. Comisión Federal para la Protección contra Riesgos Sanitarios. Alerta Sanitaria: La COFEPRIS revoca registro de producto "Kikuzubam". 28 de marzo de. 2014. http://www.google.com.mx/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&ved=0CCwQFjAC&url=http%3A%2F%2Fwww.cofepris.gob.mx%2FAS%2FDocuments%2FCOMISI%25C3%2593N%2520DE%2520OPERACI%25C3%2593N%2520SANITARIA-Documentos%2520para%2520publicar%2520en%2520la%2520secci%25C3%25B3n%2520de%2520MEDICAMENTOS%2FAlertas%2FKIKUZUBAM-28032014-.pdf&ei=D3LNVJT3K5O3yAS-0ILgCg&usg=AFQjCNE3DGEjuIq7l8heQHqbq7PXgkITiA&sig2=-QtwfdJhjkihHbjvHDPZEg&bvm=bv.85076809,d.aWw (accessed 18 Apr 2015).
32. Espinoza de la Garza CE, Perdomo-Abúndez FC, Padilla-Calderón J, et al. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis. Electrophoresis 2013;34:1133-40.